Beruflich Dokumente
Kultur Dokumente
Md, Phd
31/5/2015
Current situation
Therapies
Clinical evidence
Sensor Augmented Pump (SAP) had greater A1C reduction vs. MDI
at 3 months and sustained it over 12 months.1,2
Current situation
The problem
Therapies
Clinical evidence
1. Seaquist ER, et al. J Clin Endocrinol Metab. 2013;98(5):1845-59. 2. Pickup J et al. Diabet Med 2008;25:765-74 3. Misso ML et al. Cochrane Database Syst Rev. 2010;(1):CD005103. 4. Bergenstal
RM et al. N Engl J Med. 2013;369(3):224-32.
DIRECT COSTS
Medical Costs:
The problem
Hospital Costs:
Hypoglycemic Episode
with Hospitalization
are up to 4,830 in DE2
Indirect Costs:
3.6 missed days of work
per severe event 6
INDIRECT COSTS
Patients with hypoglycemia have shown 77% more short-term disability
days annually and a 5-fold greater risk of short-term disability the week
following a hypoglycemic event.4
Absenteeism following a mild/moderate episode during work ranges
from 9.9 hours to 14.7 hours for a nocturnal episode.5
Severe episodes among T1DM patients result in 3.6 days off work on average.6
Curkendall S et al. Endocr Pract 2009 May 1;15(4):302-12. 2. DRG Browser (2013) 3. Leese GP et al. Diabetes Care 2003 Apr 1;26(4):1176-80.
4. Rhoads GG et al. J Occup Environ Med 2005;47(5):447-52. 5. Brod M et al. Value Health 2011;14(5):665-671. 6. Davis RE et al. Curr Med Res Opin 2005;21:1477-1483.
Therapies
Clinical evidence
Executive summary
The challenges of optimally managing T1DM faced by patients, physicians, and payers can be
effectively and economically addressed with MiniMed TM 640G and SmartGuardTM
Current situation
CURRENT SITUATION
The problem
Therapies
Clinical evidence
THE PROBLEM
Hypoglycemia has a significant clinical, economic
and human burden5
T1 patients have been shown to have 1 or more severe hypo
events per year leading to significant costs and impaired
quality of life. Hypo Prone and hypo-unaware patients will
have significantly higher rates6
Reducing hypoglycemia is CRITICAL for better diabetes care
Current situation
The problem
Therapies
Clinical evidence
PERSONALIZED CONVENIENCE
Informative Bolus WizardTM
Programmable treatment reminders
Remote bolus from meter
Home Screen
Statusbar: provides
Current time
BG reading: displays a BG
taken in the last 12 minutes
Bolus:
gives you access to the bolus delivery screen and
other bolus insulin options
Benefit
A more convenient way to use a Temp Basal that is used repeatedly
without having to program it each time it is used
Details
Benefit
Allows common bolus amounts to be pre-programmed
Details:
Benefit
High accuracy
Wireless capability eliminates need to manually enter BG readings
into pump
Remote bolus capability
Communication device for CareLink
Compact, discreet design
Details
Display Screen
Selection/Scrolling Buttons
Low Limit
Trend Arrows
Most recent Sensor
Glucose (SG) Reading
Suspend by Sensor Icon
Trend Arrows
or
or
or
- SG has been rising or falling about 1-2 mmol/L over the last 20 minutes
- SG has been rising or falling about 2-3 mmol/L over the last 20 minutes
- SG has been rising or falling greater than 3 mmol/L over the last 20 minutes
High Limit
3 hr Sensor
Glucose (SG)
Graph
Low Limit
4.0 mmol/L
Low Settings
Purpose:
Provides alerts or suspends insulin delivery when sensor glucose
values are
approaching or reach the pre-set low limit
Benefit:
Helps to minimize low glucose excursions by providing alerts and/or
suspending insulin delivery
Details:
Up to 8 time segments and low limits can be set per day
Options per time segment:
Low Limit
00:000
30 01:00
60
minutes
90
02:00
120
Low Limit
00:000
30 01:00
60
minutes
90
02:00
120
Low Limit
00:000
30 01:00
60
minutes
90
02:00
120
00:000
30 01:00
60
minutes
90
02:00
120
00:000
30 01:00
60
minutes
90
02:00
120
00:000
30 01:00
60
minutes
90
02:00
120
00:000
30 01:00
60
Minutes
90
02:00
120
00:000
30 01:00
60
minutes
90
02:00
120
00:000
30 01:00
60
minutes
90
02:00
120
Messaging guide
What are the key product messages?
HCP
PATIENT
Predictive suspend
Predictive suspend
Self-test
Self-test
Messaging guide
What are the key product messages?
HCP
PATIENT
Messaging guide
What are the key product messages?
HCP
Easy training thanks to the
intuitive screen navigation
PATIENT
Less button pushing, ease of
use thanks to the intuitive screen
navigation
Current situation
The problem
Clinical evidence
Single-center observational study of 22 youths (14-20 years) where hypoglycemia was induced
by exercise while using SmartGuart technology.* The results show that SmartGuard may further
reduce the severity of hypoglycemia.
1. Danne T et al. Diabetes Technology & Therapeutics. 2014; 16(6):338:347.
*PLGM (predictive low glucose management) was suspend terminology used in the study and report. Actual brand name is SmartGuard technology.
Current situation
The problem
Therapies
*Study Design: Randomized controlled trial of 247 patients lasting 3 months comparing the MiniMed
Veo with Low Glucose Suspend off vs. with Low Glucose Suspend on; A1C control was similar in both groups
**Low-glucose insulin-suspend pumps consist of a CSII insulin pump that is linked to CGM and this automatically suspends the basal infusion rate for up to 2 h in the event of CGMdetected hypoglycaemia.
*** A nocturnal hypoglycemic event was defined as sensor glucose values of 65 mg per deciliter (3.6 mmol per liter) or less between 10 p.m. and 8 a.m. for more than 20 consecutive
minutes in the absence of a pump interaction (i.e., meter blood glucose entries, carbohydrate entries, and insulin-delivery changes) within 20 minutes, as determined by reviews of data
uploaded with the use of Medtronic CareLink Therapy Management Software for Diabetes.
Current situation
The problem
The Therapies
Study Design: Randomized controlled trial of 247 patients lasting 3 months comparing the MiniMed Veo with
Low Glucose Suspend* off vs. with Low Glucose Suspend on; A1C control was similar in both groups
*Low-glucose insulin-suspend pumps consist of a CSII insulin pump that is linked to CGM and this automatically suspends the basal infusion rate
for up to 2 h in the event of CGM-detected hypoglycaemia.
Current situation
The problem
Therapies
Clinical evidence
1. Ly TT et al. JAMA. 2013;310(12):1240-7. 2. McBride M et al. Presented ISPOR 16th. Dublin November 2013. 3. Ly TT et al. Diabetes Care 34: 50 52.2011 4. Ly TT et al. Value Health. 2014;17(5):561-9.
31/5/2015